Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Dezember 2020 06:00 ET | Quelle: Mesoblast Limited

FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States...
19. November 2020 17:36 ET | Quelle: Mesoblast Limited

Operational and Financial Results for the Period Ended September 30, 2020

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational and...
19. November 2020 17:12 ET | Quelle: Mesoblast Limited

Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-L

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), today announced that it has entered into an exclusive worldwide license and collaboration agreement with...
19. November 2020 16:19 ET | Quelle: Mesoblast Limited

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a...
11. November 2020 06:00 ET | Quelle: Mesoblast Limited

Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Remestemcel-L Phase 3 Trial in COVID-19 ARDS

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to...
29. Oktober 2020 06:00 ET | Quelle: Mesoblast Limited

Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHD

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
22. Oktober 2020 06:00 ET | Quelle: Mesoblast Limited

Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn’s Disease and Ulcerative Colitis

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a randomized,...
13. Oktober 2020 06:00 ET | Quelle: Mesoblast Limited

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the randomized...
01. Oktober 2020 19:25 ET | Quelle: Mesoblast Limited

Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the US Food and...
15. September 2020 06:00 ET | Quelle: Mesoblast Limited

Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its lead product...

Vorherige Seite

Nächste Seite